Only 11 Himachal Pharma Units Fully Meet New GMP Rules, Raising Drug Quality Concerns

Spread the Message

Read Time:7 Minute, 14 Second

Shimla: A recent enforcement drive of India’s revised Schedule M Good Manufacturing Practices (GMP) has revealed that only 10–11 out of roughly 90 inspected pharmaceutical manufacturing units in Himachal Pradesh are fully compliant with the new norms, putting a spotlight on quality gaps in one of the country’s largest medicine hubs. The findings, reported this week, come after the expiry of transition deadlines for micro, small and medium enterprises (MSMEs), and have triggered warning notices to about 80 units for serious deficiencies that must be corrected to avoid license suspension or closure.

What the crackdown found

Regulators in Himachal Pradesh inspected around 90 drug manufacturing units once the revised Schedule M deadline passed and found that barely a tenth met all updated GMP requirements. Notices were issued to nearly 80 units, highlighting problems ranging from inadequate infrastructure and poor documentation to gaps in process validation and quality assurance systems.

Officials say the current drive is part of a broader risk‑based inspection campaign that has brought nearly 370 micro, small and medium pharma units across the state under scrutiny. Himachal Pradesh hosts more than 600 pharmaceutical units overall, making it one of India’s largest manufacturing clusters and a major supplier of generic medicines nationwide.

What is revised Schedule M and why it matters

Schedule M is a section of India’s Drugs and Cosmetics Rules that spells out GMP requirements for pharmaceutical manufacturing premises, equipment and processes. In December 2023, the Central Drugs Standard Control Organisation (CDSCO) notified a substantially revised Schedule M aimed at harmonising Indian standards with global benchmarks such as WHO‑GMP and PIC/S guidelines.

Key updates move the regime from a basic checklist approach to a systems‑driven quality framework that emphasises:

Scientific facility design and controlled cleanroom environments.
Lifecycle‑based validation of equipment and processes.
Data integrity, electronic records and stronger documentation practices.
Formal quality risk management and continuous monitoring.

MSME units were expected to comply by mid‑2024 and larger companies by late 2024, with regulators signalling that non‑compliance could lead to suspension or cancellation of manufacturing licenses. The aim is to reduce risks of contamination, substandard potency and inconsistent product quality that can directly impact patient safety.

Why Himachal’s pharma hub is under pressure

Himachal Pradesh, particularly the Baddi‑Barotiwala‑Nalagarh (BBN) industrial belt, has evolved into a major pharma manufacturing hub over the past two decades, housing hundreds of plants that supply an estimated one‑third of India’s total pharmaceutical output. The cluster includes both multinational facilities and a large number of contract manufacturers providing third‑party production for brands across India.

Out of about 655 units in the state, earlier estimates suggested roughly 251 were already GMP‑certified under the older norms, leaving more than 400 units needing upgrades to meet the revised Schedule M standards. Industry associations have warned that many of these units operate on thin margins and face significant financial and technical hurdles in overhauling infrastructure, utilities and quality systems within tight timelines.

Regulators, however, maintain that tighter oversight is needed after several high‑profile international alerts on the quality of exported cough syrups and other products from India in recent years. Strengthening GMP in key hubs like Himachal is seen as critical to restoring confidence in Indian generics at home and abroad.

What regulators and experts are saying

State drug control officials have issued a clear warning: units that fail to fix deficiencies flagged during inspections risk strict action, including suspension or cancellation of licenses and possible closure. At the same time, they have clarified that media reports suggesting dozens of immediate shutdowns may be exaggerated, noting that only a small number have so far voluntarily surrendered or lost licenses during the verification process.

Central regulators see the revised Schedule M as a non‑negotiable baseline rather than an aspirational target. Training programmes and guidance documents have been rolled out nationwide to help manufacturers understand expectations around quality risk management, validation and documentation. The Union Health Ministry is also reportedly considering limited deadline extensions or phased implementation for certain firms, but has not indicated any dilution of core standards.

Independent regulatory and quality experts broadly support the crackdown but caution that the transition will be painful for smaller units. They argue that failing to invest in modern GMP systems could ultimately prove more costly if it leads to product recalls, export bans or loss of market trust.

Industry concerns: cost, time and capacity

Industry bodies representing MSME pharma units in Himachal have argued that one year is insufficient to complete costly upgrades such as HVAC modernisation, cleanroom redesign, equipment qualification and digitalisation of records. Although the central government has announced subsidy schemes of up to ₹1 crore per unit to support infrastructure and WHO‑GMP implementation, manufacturers say this covers only a fraction of actual costs for full compliance.

Smaller firms also report struggles in accessing specialised technical expertise, validation services and trained quality personnel, especially in remote or semi‑urban industrial clusters. Some have requested a three‑year extension to spread out investments and minimise disruption to production and employment.

Experts highlight that without targeted support – such as concessional financing, shared testing facilities or cluster‑level technical assistance – there is a real risk that a portion of MSME units may shut down rather than upgrade. That could affect local jobs and reduce competition in certain generic segments, potentially impacting affordability in the long term.

What this means for patients and public health

For patients, the immediate concern is whether non‑compliance in manufacturing units compromises the safety and effectiveness of medicines. GMP gaps raise the risk of problems such as microbial contamination, incorrect dosage strength or impurities, which can make treatments less effective or, in rare cases, harmful. The revised Schedule M is specifically designed to reduce these risks by embedding stronger controls throughout the manufacturing lifecycle.

At the same time, aggressive enforcement can create short‑term supply disruptions if multiple units halt production to upgrade or if licenses are suspended. Regulators are therefore under pressure to balance strict quality enforcement with careful management of essential drug availability, including redirecting demand to compliant facilities and monitoring for price spikes or shortages.

For now, there is no evidence that the recent inspections in Himachal have led to widespread shortages of critical medicines, but experts advise patients not to discontinue prescribed treatments without consulting their healthcare providers. Pharmacists and hospitals may gradually adjust procurement preferences toward units with clear evidence of compliance, which could shift market share within the state’s pharma ecosystem.

Practical takeaways for readers

For health‑conscious consumers and patients:

Continue taking prescribed medicines unless your doctor advises a change; do not stop chronic therapies on your own because of regulatory news.
When possible, use medicines from reputable, well‑known manufacturers, especially for critical therapies such as antibiotics, heart drugs and insulin.
Report any suspected side effects or quality issues – such as unusual odour, discoloration or packaging defects – to your doctor, pharmacist or local drug control authority.

For healthcare professionals:

Stay updated on regulatory advisories and product recalls affecting your region to guide safe prescribing and dispensing.
Consider procurement policies that prioritise suppliers with documented compliance to revised Schedule M or WHO‑GMP, particularly for high‑risk products like sterile injectables.
Educate patients that heightened oversight is intended to improve medicine safety rather than cause alarm, and encourage them to discuss concerns rather than self‑adjusting treatment.

For policymakers and industry leaders:

Align financial support, low‑interest credit and technical assistance with the scale of upgrades required, especially for MSME units in clusters like Baddi.
Explore shared services models – such as common testing labs or validation support centres – to help smaller plants meet data integrity and validation requirements.
Maintain transparency about inspection outcomes and timelines while ensuring that enforcement does not compromise access to essential medicines for vulnerable populations.

The situation in Himachal Pradesh highlights a broader national challenge: upgrading India’s vast and diverse manufacturing base to match international GMP expectations without undermining the affordability and availability of its generic medicines. How regulators, industry and policymakers navigate this transition in key hubs will likely shape both public health outcomes and the global reputation of Indian pharmaceuticals in the years ahead.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.